首页> 美国卫生研究院文献>Mayo Clinic Proceedings >Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae Carbapenem-Resistant Enterobacteriaceae and Multidrug-Resistant Pseudomonas aeruginosa
【2h】

Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae Carbapenem-Resistant Enterobacteriaceae and Multidrug-Resistant Pseudomonas aeruginosa

机译:针对抗革兰氏阴性菌的抗菌治疗的当前概念:广谱β-内酰胺酶生产肠杆菌科碳青霉烯耐药肠杆菌科和多药耐药铜绿假单胞菌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The development of antimicrobial resistance among gram-negative pathogens has been progressive and relentless. Pathogens of particular concern include extended-spectrum β-lactamase–producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Classic agents used to treat these pathogens have become outdated. Of the few new drugs available, many have already become targets for bacterial mechanisms of resistance. This review describes the current approach to infections due to these resistant organisms and elaborates on the available treatment options.
机译:革兰氏阴性病原体中抗菌素耐药性的发展是不断进行的。特别令人关注的病原体包括产生广谱β-内酰胺酶的肠杆菌科细菌,对碳青霉烯类耐药的肠杆菌科细菌和对多药耐药的铜绿假单胞菌。用于治疗这些病原体的经典药物已经过时。在少数可用的新药中,许多已成为细菌耐药机制的靶标。这篇综述描述了由于这些耐药生物导致的当前感染方法,并详细介绍了可用的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号